Price Alert

Innovent Biologics Inc. (IVBXF)

OTC: IVBXF · Real-Time Price · USD

12.72

0.34 (2.75%)

At close: Oct 03, 2025, 1:56 PM

12.50

-1.73%

After-hours: Oct 02, 2025, 12:07 PM EDT

Innovent Biologics Statistics

Share Statistics

Innovent Biologics has 1.71B shares outstanding. The number of shares has increased by 4.36% in one year.

Shares Outstanding	1.71B
Shares Change (YoY)	4.36%
Shares Change (QoQ)	3.5%
Owned by Institutions (%)	n/a
Shares Floating	1.53B
Failed to Deliver (FTD) Shares	n/a
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 20.12K, so 0% of the outstanding shares have been sold short.

Short Interest	20.12K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.05

Valuation Ratios

The PE ratio is -547.41 and the forward PE ratio is 12.51. Innovent Biologics's PEG ratio is 6.

PE Ratio	-547.41
Forward PE	12.51
PS Ratio	5.5
Forward PS	1.4
PB Ratio	3.95
P/FCF Ratio	-123.81
PEG Ratio	6

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Innovent Biologics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.22.

Current Ratio	2.35
Quick Ratio	2.16
Debt / Equity	0.22
Debt / EBITDA	-5.89
Debt / FCF	-6.77
Interest Coverage	-11.17

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$1.66M
Profits Per Employee	$-16.72K
Employee Count	5,659
Asset Turnover	0.44
Inventory Turnover	1.84

Taxes

Income Tax	16.01M
Effective Tax Rate	-20.36%

Stock Price Statistics

The stock price has increased by 112% in the last 52 weeks. The beta is 0.23, so Innovent Biologics's price volatility has been higher than the market average.

Beta	0.23
52-Week Price Change	112%
50-Day Moving Average	12.46
200-Day Moving Average	8.03
Relative Strength Index (RSI)	54.45
Average Volume (20 Days)	46,118

Income Statement

In the last 12 months, Innovent Biologics had revenue of 9.42B and earned -94.63M in profits. Earnings per share was -0.06.

Revenue	9.42B
Gross Profit	7.91B
Operating Income	-755.87M
Net Income	-94.63M
EBITDA	-480.28M
EBIT	-755.87M
Earnings Per Share (EPS)	-0.06

Full Income Statement

Balance Sheet

The company has 7.51B in cash and 2.83B in debt, giving a net cash position of 4.68B.

Cash & Cash Equivalents	7.51B
Total Debt	2.83B
Net Cash	4.68B
Retained Earnings	-15.91B
Total Assets	21.6B
Working Capital	5.9B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.29B and capital expenditures -1.71B, giving a free cash flow of -418.39M.

Operating Cash Flow	1.29B
Capital Expenditures	-1.71B
Free Cash Flow	-418.39M
FCF Per Share	-0.27

Full Cash Flow Statement

Margins

Gross margin is 83.97%, with operating and profit margins of -8.02% and -1%.

Gross Margin	83.97%
Operating Margin	-8.02%
Pretax Margin	-0.83%
Profit Margin	-1%
EBITDA Margin	-5.1%
EBIT Margin	-8.02%
FCF Margin	-4.44%

Dividends & Yields

IVBXF does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for IVBXF.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	2.16
Piotroski F-Score	3